Articles tagged with Egfr Signaling
A new drug targeting RAS, a pathologically altered protein causing 40% of colorectal and 90% of pancreatic cancers, has been developed. The molecular eraser, RIBOTAC, stops the production of RAS by degrading its mRNA, but surprisingly triggers changes in cancer cells despite minimal impact on protein quantity.
A study published in JAMA finds that using different methods to estimate glomerular filtration rate (eGFR) can lead to significant discrepancies, particularly for those with chronic kidney disease. The findings suggest that cystatin C-based eGFR may be more accurate in predicting clinical outcomes.
Researchers identified RTK dependent and independent mechanisms of resistance to EGFR targeted therapies in breast and head and neck cancers, highlighting opportunities for combination therapies and biomarker identification.
Researchers at Osaka University uncovered the molecular details of how Drosophila fruit fly cells are removed during development, challenging the common assumption that clustered apoptosis poses a disadvantage to organisms. This study may help determine how abnormal cell death leads to congenital defects in humans.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
A new link has been discovered between FBXW7 mutations and EGFR signaling activity in colorectal cancer. The study found that the mutated form of the FBXW7 gene could no longer degrade the EGFR protein, leading to increased signaling activity and a decreased response to anti-EGFR treatment.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers identified distinct genomic characteristics that impact prognosis for patients with triple negative apocrine carcinoma. The study confirmed a five-year disease-free survival rate of 92.2% for these patients, significantly higher than those diagnosed with other types of TNBC.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
A Japanese research team identified two critical signaling pathways regulating stem cell differentiation in the stomach, promoting healthy homeostasis and protecting against gastric diseases. The study, published in Nature Communications, sheds light on the mechanisms behind cellular renewal and differentiation.
A recent study elucidated the role of EGF and its downstream signaling cascade in controlling oral keratinocyte behavior, offering new insights for pharmacological manipulation. The findings suggest that activating the EGF/EGFR pathway can enhance oral keratinocyte motility and proliferation.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers have discovered that intestinal bacteria can lead to more severe adhesions after abdominal surgery. The study found that mesothelial cells and EGFR signaling play a crucial role in the formation of these adhesions. The findings suggest that targeting EGFR may be a potential approach to reducing adhesion risk.
The loss of expression of a microtubule/tubulin binding protein, centrosomal protein 4.1-associated protein, causes increased EGFR levels and signaling in oral squamous cell carcinoma cells. Depletion of CPAP enhances tumorigenicity, while EGFR depletion attenuates EMT features.
Researchers have identified a potential new approach to restore hearing loss by activating the EGF receptor signaling pathway in cochlear support cells. The study found that this pathway can trigger cell proliferation and regeneration of sensory hair cells, which may lead to improved hearing restoration.
A team of neuroscientists at Columbia University has figured out how to tease apart the many roles EGFR plays in the body. They report their findings in PLOS Genetics, solving a long-standing question about EGFR signaling and development. The study sheds light on the link between EGFR and disease, offering clues for diseases like cancer.
Researchers discovered that CD44s plays a key role in sustaining EGFR signaling in glioblastoma multiforme, allowing cancer cells to survive. Removing CD44s from the cell surface reduces the growth of glioblastoma cells and increases sensitivity to erlotinib treatment.
Scientists have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells. The study shows how the metabolic signposts of cancer cell growth can be predicted based on EGFR signaling genes.
UT Southwestern Medical Center researchers have identified a cell signaling mechanism that plays a crucial role in brain cancer growth and may provide a new therapeutic target. Non-canonical epidermal growth factor receptor (EGFR) signaling is highly active in glioblastomas, making tumor cells more resistant to chemotherapy treatment.
Researchers have discovered that protein Shc acts as a tumor suppressor by binding to and blocking the activation of cancer-promoting protein Erk. This finding has significant implications for treating various types of cancer, including ovarian and prostate cancer.
Researchers identify a unique mechanism by which glioblastoma cells develop resistance to EGFR-targeting drugs by hijacking the signaling of PDGFRβ. Targeting both receptors simultaneously prevents resistance and suppresses tumors in laboratory models.
Insect metamorphosis triggered by hormones, like puberty in humans, involves a global change of rules for gene expression. Researchers found that a specific gene and signaling pathway work together to control development at different stages.
Researchers at Stanford Medicine have discovered a gene deletion in up to one-fourth of glioblastoma cases, a type of brain cancer with poor survival prospects. The deletion contributes to tumor growth, resistance to therapy, and worsens patient outcomes.
A global signaling study suggests that cancer's genesis may be linked to the haphazard activation of secondary signaling pathways by proteins. The researchers found that only two human ErbB receptors, EGFR and ErbB2, become promiscuous when overexpressed, recruiting a large number of different signaling proteins.
Researchers found that the Hrs protein regulates cell proliferation by tagging receptors for degradation through a process called endocytosis. This finding could lead to new cancer treatments targeting the Hrs protein.
Researchers studying Drosophila flies have identified key molecules regulating epidermal growth factor receptor signalling, which is crucial for developmental processes and cell growth. The study's findings have implications for understanding human diseases like cancer, with potential applications in medical advances.